Literature DB >> 17698686

Defining the population-based burden of nosocomial pneumococcal bacteremia.

Outi Lyytikäinen1, Peter Klemets, Petri Ruutu, Tarja Kaijalainen, Merja Rantala, Jukka Ollgren, J Pekka Nuorti.   

Abstract

BACKGROUND: The characteristics, risk factors, and outcome of patients with nosocomial pneumococcal bacteremia (NPB) have not been described in large, population-based studies.
METHODS: All episodes of invasive pneumococcal infections reported by Finnish clinical microbiology laboratories (positive blood or cerebrospinal fluid culture) from January 1, 1995, through December 31, 2002, were linked to data in national health care registries and vital statistics to obtain information on the patient's preceding hospitalizations, comorbidities, and outcome of illness. Pneumococcal bacteremia was defined as nosocomial if the first positive blood culture was obtained more than 2 days after hospital admission, or if the patient had been hospitalized for more than 2 days within 7 days of the first positive blood culture.
RESULTS: Information on hospital admission was available for 4217 of 4357 persons (96.8%) with invasive pneumococcal infections. We identified 387 NPBs (9.7%) among 3973 pneumococcal bacteremias. Patients with NPB were older (median age, 67 years vs 52 years; P < .001) and were more likely to have at least 1 high-risk condition (other than age > or = 65 years), for which 23-valent pneumococcal polysaccharide vaccine is recommended (59.2% vs 34.6%; P < .001), compared with patients who had community-associated pneumococcal bacteremias. The case fatality proportion at 28 days was higher in patients with NPB than in those with community-associated pneumococcal bacteremias (23.8% vs 10.8%; P < .001). Pneumococcal serotypes included in 23-valent polysaccharide vaccine and 7-valent conjugate vaccine caused 71.5% and 46.1% of NPBs, respectively.
CONCLUSIONS: A substantial proportion of pneumococcal bacteremias are health care associated. The high prevalence of conditions for which pneumococcal polysaccharide vaccine is recommended provides opportunities for strengthening prevention efforts in these patients at high risk of illness and death.

Entities:  

Mesh:

Year:  2007        PMID: 17698686     DOI: 10.1001/archinte.167.15.1635

Source DB:  PubMed          Journal:  Arch Intern Med        ISSN: 0003-9926


  5 in total

Review 1.  Epidemiology of antimicrobial resistance in bloodstream infections.

Authors:  Murat Akova
Journal:  Virulence       Date:  2016-04-02       Impact factor: 5.882

Review 2.  Population-based epidemiology and microbiology of community-onset bloodstream infections.

Authors:  Kevin B Laupland; Deirdre L Church
Journal:  Clin Microbiol Rev       Date:  2014-10       Impact factor: 26.132

3.  Invasive Pneumococcal Disease Characterization in Adults and Subgroups aged < 60 years and ≥ 60 years in Bogota, Colombia.

Authors:  Aura Lucia Leal Castro; Germán Camacho-Moreno; Anita Montañez-Ayala; Fabio Varón-Vega; José Camilo Alvarez-Rodríguez; Sandra Valderrama-Beltrán; Beatriz Elena Ariza; Oscar Pancha; Ana Yadira Santana; Nella Sánchez Flórez; Patricia Reyes; Jaime Ruiz; Claudia Beltran; Emilia Prieto; Monica Rojas; Juan Urrego-Reyes; Cintia Irene Parellada
Journal:  IJID Reg       Date:  2022-04-28

4.  The outcome and timing of death of 17,767 nosocomial bloodstream infections in acute care hospitals in Finland during 1999-2014.

Authors:  Keiju S K Kontula; Kirsi Skogberg; Jukka Ollgren; Asko Järvinen; Outi Lyytikäinen
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2018-02-17       Impact factor: 3.267

5.  Estimating the burden of healthcare-associated infections caused by selected multidrug-resistant bacteria Finland, 2010.

Authors:  Mari Kanerva; Jukka Ollgren; Antti J Hakanen; Outi Lyytikäinen
Journal:  Antimicrob Resist Infect Control       Date:  2012-10-19       Impact factor: 4.887

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.